Forty Seven Inc. (FTSV)’s Financial Results Comparing With Aduro BioTech Inc. (NASDAQ:ADRO)

This is therefore a comparing of the profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation in Forty Seven Inc. (NASDAQ:FTSV) and Aduro BioTech Inc. (NASDAQ:ADRO). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Forty Seven Inc. N/A 0.00 65.49M -2.06 0.00
Aduro BioTech Inc. 15.09M 21.77 95.36M -1.17 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Forty Seven Inc. and Aduro BioTech Inc.

Profitability

Table 2 shows us the net margins, return on equity and return on assets of both companies.

Net Margins Return on Equity Return on Assets
Forty Seven Inc. 0.00% 0% 0%
Aduro BioTech Inc. -631.94% -57.2% -24.6%

Liquidity

Forty Seven Inc.’s Current Ratio is 11.9 while its Quick Ratio is 11.9. On the competitive side is, Aduro BioTech Inc. which has a 9.3 Current Ratio and a 9.3 Quick Ratio. Forty Seven Inc. is better positioned to pay off short and long-term obligations compared to Aduro BioTech Inc.

Analyst Ratings

The table shown features the ratings and recommendations for Forty Seven Inc. and Aduro BioTech Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Forty Seven Inc. 0 0 0 0.00
Aduro BioTech Inc. 0 0 2 3.00

Competitively the consensus price target of Aduro BioTech Inc. is $8.5, which is potential 106.31% upside.

Insider and Institutional Ownership

Roughly 67.3% of Forty Seven Inc. shares are owned by institutional investors while 50.7% of Aduro BioTech Inc. are owned by institutional investors. 5.1% are Forty Seven Inc.’s share owned by insiders. On the other hand, insiders owned about 1.4% of Aduro BioTech Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Forty Seven Inc. 1.35% 17.43% -6.15% 12.09% 0% 9.73%
Aduro BioTech Inc. -0.24% 40.6% 64.96% -33.49% -31.87% 58.71%

For the past year Forty Seven Inc. has weaker performance than Aduro BioTech Inc.

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. The company is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract. In addition, it is developing STING Pathway Activator product candidates that are synthetic small molecule immune modulators, which target and activate Stimulator of Interferon Genes receptor under collaboration with Novartis Pharmaceuticals Corporation; and product candidates that address other therapeutic areas, such as autoimmune and infectious diseases. Further, the companyÂ’s products pipeline comprises BION-1301, a B-select mAb novel therapy for multiple myeloma; and antibody product candidates, including APRIL for the treatment of multiple myeloma, as well as oncology therapies, such as CD27, PD-1, and CTLA-4. Aduro BioTech, Inc. has development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints; and collaboration agreement with Janssen Biotech, Inc. and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.